ITEMS IN AFP WITH KEYWORD:
Deep Venous Thrombosis
Vitamin K antagonists reduce the recurrence of DVT and VTE (number needed to treat [NNT] = 17; 95% CI, 13 to 48) but not pulmonary embolism (PE) compared with no anticoagulation or placebo.
Perhaps it is time to start thinking about VTE as a chronic disease. Approximately one in 10 patients that have a VTE will have a second VTE over the next 12 months and almost four in 10 will have a second VTE over 10 years.
Dec 15, 2019 Issue
Diagnosing DVT in Nonpregnant Adults in the Primary Care Setting [Point-of-Care Guides]
What is the best approach to the evaluation of nonpregnant adults with suspected first lower extremity deep venous thrombosis (DVT) in the outpatient primary care setting?
Dec 1, 2019 Issue
Diagnosing VTE: Guidelines from the American Society of Hematology [Practice Guidelines]
The American Society of Hematology has published recommendations for determining the optimal diagnostic strategy based on pretest risk.
Vitamin K antagonists, unfractionated heparin, low-molecular-weight heparin, and direct oral anticoagulants are commonly used for the prevention and treatment of systemic embolism associated with atrial fibrillation, stroke, and venous thromboembolism. Low-molecular-weight heparin and select direct oral anticoagulants can be used for anticoagulation therapy initiation on an outpatient basis. Indications for anticoagulation therapy and other related recommendations from guidelines are discussed in this article.
This study found no benefit to the addition of intermittent pneumatic compression to pharmacologic anticoagulation for the prevention of proximal DVT in critically ill patients.
Jun 1, 2019 Issue
Anticoagulation for the Long-term Treatment of VTE in Patients with Cancer [Cochrane for Clinicians]
Low-molecular-weight heparin (LMWH), vitamin K antagonists, and direct oral anticoagulants, when used to prevent recurrent VTE, have a similar impact on all-cause mortality.
Dec 1, 2018 Issue
Deep Venous Thrombosis: Home vs. Inpatient Treatment [Cochrane for Clinicians]
Patients treated at home with low-molecular-weight heparin (LMWH) have lower rates of recurrent VTE than those treated in a hospital.
Extended prophylaxis with low-dose aspirin is similar in efficacy to rivaroxaban for the prevention of symptomatic VTE following TKA or THA. Aspirin is cheap, widely available, and effective, making it a good alternative to the more costly direct oral anticoagulants.
Jun 1, 2018 Issue
High-Dose vs. Standard-Dose Heparin for VTE Prophylaxis in Obese Patients [FPIN's Help Desk Answers]
In most patients weighing more than 220 lb (100 kg), high-dose heparin prophylaxis (7,500 units subcutaneously three times per day) does not further reduce the risk of VTE compared with standard-dose heparin (5,000 units subcutaneously two or three times per day).